Adalimumab in pediatric Crohn's disease

Ashish S. Patel, Lisbet D. Suarez, Joel R. Rosh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Adalimumab, a human monoclonal antibody to tumor necrosis factor alpha (TNF-α), was initially approved for the treatment of moderate to severe rheumatoid arthritis in 2002. In the subsequent years, its anti-inflammatory properties were applied to the treatment of psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease (CD), plaque psoriasis, polyarticular juvenile idiopathic arthritis, adult ulcerative colitis and most recently in 2014, pediatric CD. The biologic era in pediatric CD has changed and redefined the therapeutic approach to this challenging lifelong disease. This article summarizes the clinical legacy of adalimumab with a focus on its most recent expanded indication, pediatric CD.

Original languageEnglish (US)
Pages (from-to)127-133
Number of pages7
JournalImmunotherapy
Volume8
Issue number2
DOIs
StatePublished - Feb 2016

Fingerprint

Psoriatic Arthritis
Juvenile Arthritis
Ankylosing Spondylitis
Ulcerative Colitis
Psoriasis
Crohn Disease
Rheumatoid Arthritis
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Adalimumab
Pediatric Crohn's disease
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Patel, Ashish S. ; Suarez, Lisbet D. ; Rosh, Joel R. / Adalimumab in pediatric Crohn's disease. In: Immunotherapy. 2016 ; Vol. 8, No. 2. pp. 127-133.
@article{fe8589a19c6a4e4fa0b70c28d3691a72,
title = "Adalimumab in pediatric Crohn's disease",
abstract = "Adalimumab, a human monoclonal antibody to tumor necrosis factor alpha (TNF-α), was initially approved for the treatment of moderate to severe rheumatoid arthritis in 2002. In the subsequent years, its anti-inflammatory properties were applied to the treatment of psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease (CD), plaque psoriasis, polyarticular juvenile idiopathic arthritis, adult ulcerative colitis and most recently in 2014, pediatric CD. The biologic era in pediatric CD has changed and redefined the therapeutic approach to this challenging lifelong disease. This article summarizes the clinical legacy of adalimumab with a focus on its most recent expanded indication, pediatric CD.",
author = "Patel, {Ashish S.} and Suarez, {Lisbet D.} and Rosh, {Joel R.}",
year = "2016",
month = "2",
doi = "10.2217/imt.15.114",
language = "English (US)",
volume = "8",
pages = "127--133",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "2",

}

Adalimumab in pediatric Crohn's disease. / Patel, Ashish S.; Suarez, Lisbet D.; Rosh, Joel R.

In: Immunotherapy, Vol. 8, No. 2, 02.2016, p. 127-133.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adalimumab in pediatric Crohn's disease

AU - Patel, Ashish S.

AU - Suarez, Lisbet D.

AU - Rosh, Joel R.

PY - 2016/2

Y1 - 2016/2

N2 - Adalimumab, a human monoclonal antibody to tumor necrosis factor alpha (TNF-α), was initially approved for the treatment of moderate to severe rheumatoid arthritis in 2002. In the subsequent years, its anti-inflammatory properties were applied to the treatment of psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease (CD), plaque psoriasis, polyarticular juvenile idiopathic arthritis, adult ulcerative colitis and most recently in 2014, pediatric CD. The biologic era in pediatric CD has changed and redefined the therapeutic approach to this challenging lifelong disease. This article summarizes the clinical legacy of adalimumab with a focus on its most recent expanded indication, pediatric CD.

AB - Adalimumab, a human monoclonal antibody to tumor necrosis factor alpha (TNF-α), was initially approved for the treatment of moderate to severe rheumatoid arthritis in 2002. In the subsequent years, its anti-inflammatory properties were applied to the treatment of psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease (CD), plaque psoriasis, polyarticular juvenile idiopathic arthritis, adult ulcerative colitis and most recently in 2014, pediatric CD. The biologic era in pediatric CD has changed and redefined the therapeutic approach to this challenging lifelong disease. This article summarizes the clinical legacy of adalimumab with a focus on its most recent expanded indication, pediatric CD.

UR - http://www.scopus.com/inward/record.url?scp=84956963408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956963408&partnerID=8YFLogxK

U2 - 10.2217/imt.15.114

DO - 10.2217/imt.15.114

M3 - Article

C2 - 26787222

AN - SCOPUS:84956963408

VL - 8

SP - 127

EP - 133

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 2

ER -